Related Experiment Video

Updated: Nov 10, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models

Michal Kopczynski1, Malgorzata Statkiewicz1, Magdalena Cybulska1

  • 1Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

International Journal of Molecular Sciences
|April 3, 2021
PubMed

Insights

A new chimeric protein, AD-O51.4, shows promise in fighting colorectal cancer (CRC) by selectively inducing cancer cell death. Researchers identified resistance mechanisms involving reduced receptor expression, paving the way for clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells.
  • Developing novel therapeutics targeting cancer cell death pathways is crucial.

Purpose of the Study:

  • To evaluate the anticancer efficacy of the chimeric AD-O51.4 protein against colorectal cancer (CRC) models.
  • To investigate mechanisms of acquired resistance to AD-O51.4 in CRC.

Main Methods:

  • Tested AD-O51.4 activity in nine human colorectal cancer cell lines and patient-derived xenografts (PDXs).
  • Quantitatively compared apoptotic activity with native TRAIL.
  • Assessed receptor abundance, apoptosis-related proteins (Caspase-8, HSP60, p53), and surface receptor expression in resistant cell lines.

Main Results:

  • AD-O51.4 demonstrated dose-dependent toxicity in seven of nine CRC cell lines.
  • Apoptotic activity correlated with TRAIL receptor abundance.
  • AD-O51.4 effectively reduced CRC PDX tumor growth.
  • Acquired resistance was associated with decreased surface TRAIL receptor and apoptosis-related protein expression.

Conclusions:

  • AD-O51.4 exhibits significant anticancer efficacy in preclinical colorectal cancer models.
  • Reduced TRAIL receptor expression is a key mechanism of acquired AD-O51.4 resistance.
  • AD-O51.4 is a promising candidate for clinical development in CRC treatment.
Keywords:
PDXTRAILapoptosiscolorectal cancer

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.4K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.4K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K